论文部分内容阅读
目的:探讨尿激酶型纤溶酶原激活因子受体在人脑胶质瘤发生发展中的作用及靶向阻断对胶质瘤生长的影响。方法:采用人脑胶质瘤细胞U87MG建立高度重复性原位裸小鼠人脑胶质瘤模型,皮下应用鼠PEG-uPA 1-48(300μg)或人PEG-uPA 1-48(300μg)或者二者联合(各100μg)每周2次。结果:对照组9周内死亡,人PEG-uPA 1-48治疗组12周内死亡,20周后有20%鼠PEG-uPA 1-48治疗组和80%联合治疗组生存。组织学检测显示鼠PEG-uPA 1-48治疗组和联合治疗组肿瘤组织血管密度、细胞增殖指数显著降低,肿瘤细胞凋亡指数显著增加。结论:uPAR在胶质瘤的恶性演进中起重要作用,Peg-uPA能有效抑制脑胶质瘤生长,对脑胶质瘤辅助治疗有用。
Objective: To investigate the role of urokinase-type plasminogen activator receptor in the development of human glioma and the effect of targeted block on the growth of glioma. METHODS: A highly reproducible in situ nude mouse model of human glioma was established using human glioma U87MG cells either subcutaneously with either mouse PEG-uPA 1-48 (300 μg) or human PEG-uPA 1-48 (300 μg) or The two combined (100μg each) twice a week. Results: The control group died within 9 weeks. The PEG-uPA 1-48 treatment group died within 12 weeks. After 20 weeks, 20% PEG-uPA 1-48 treatment group and 80% combination treatment group survived. Histological examination showed that the vascular density, the cell proliferation index and the apoptosis index of tumor cells in PEG-uPA 1-48 group and combination group were significantly increased. Conclusion: uPAR plays an important role in the malignant progression of glioma. Peg-uPA can effectively inhibit the growth of glioma and is useful for the adjuvant treatment of glioma.